In This Article:
Release Date: May 08, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
DLH Holdings Corp (NASDAQ:DLHC) successfully reduced its debt by $15.3 million in the second quarter, ahead of schedule for mandatory payments through March 2026.
-
The company generated strong operating cash flow of $14.5 million, improving its financial position.
-
DLH Holdings Corp (NASDAQ:DLHC) secured a significant contract with the US Army's Medical Research and Development Command, highlighting its capabilities in advanced technology services.
-
The company has a robust pipeline with more than $3.5 billion in opportunities, indicating potential for future growth.
-
DLH Holdings Corp (NASDAQ:DLHC) is well-positioned to benefit from the current administration's focus on efficiency and cost-cutting, aligning with its strategic capabilities.
Negative Points
-
Revenue for the second quarter decreased to $89.2 million from $101 million in the prior year, primarily due to the conversion of certain contracts to small business set-asides.
-
EBITDA decreased to $9.4 million from $10.2 million last year, reflecting lower revenue levels.
-
The company faces uncertainty due to potential impacts from government program terminations and budget cuts.
-
There is ongoing pressure from small business set-asides, which may continue to affect revenue through the third quarter.
-
Administrative delays and oversight from the new administration have slowed down contract awards, impacting the timing of revenue realization.
Q & A Highlights
Q: Can you provide an update on the revenue run rate for the CMOP contracts for the rest of the year? A: We expect the quarterly run rate to be around $23 to $25 million for the remaining locations. The six-month extension provides better assurance for revenue contribution in the third and fourth quarters. - Katherine John Bull, CFO
Q: Were you involved in the NIH's long-term women's health study that was recently shut down, and how might NIH business be impacted by such efforts? A: We were not involved in that study. While the administration has taken a tough stance on grant-funded research, we believe the overall budgetary impact will be neutral to slightly positive for us. We continue to see demand for our services, including at NIH. - Zach Parker, CEO
Q: How far along are we with the small business set-asides, and when will this stop being a significant factor in quarterly calls? A: We expect the impact of small business set-asides to continue through Q3, with revenue effects trailing into Q4. Some opportunities are still under pressure, but we anticipate stabilization by the end of the fiscal year. - Zach Parker, CEO